Fda Grants Orphan Drug Designation To Mitapivat For Treatment Of Thalassaemia

Filter Type: All Time (18 Result) Past 24 Hours Past Week Past monthFacebook Share Twitter Share LinkedIn Share Pinterest Share Reddit Share E-Mail Share

Listing Results Fda Grants Orphan Drug Designation To Mitapivat For Treatment Of Thalassaemia

1 hours ago FDA Grants Orphan Drug Designation to Mitapivat for Treatment of Thalassaemia, Agios Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company’s first-in-class pyruvate kinase-R (PKR) activator Mitapivat for the treatment of patients with NTDT α- and β-thalassaemia.

Estimated Reading Time: 2 mins

Preview / Show more

See Also: Fda orphan medicines programShow details

1 hours ago Jun 09, 2020 · The FDA has granted orphan drug designation to Agios Pharmaceuticals’ first-in-class pyruvate kinase-R (PKR) activator mitapivat for the treatment of patients with …

Preview / Show more

See Also: Orphan medicine grantShow details

4 hours ago Agios Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the …

Estimated Reading Time: 2 mins

Preview / Show more

See Also: Family MedicalShow details

3 hours ago Jun 08, 2020 · The FDA’s Office of Orphan Drug Products grants orphan status to support the development of medicines for underserved patient populations, or rare disorders, that affect …

Preview / Show more

See Also: Family MedicalShow details

6 hours ago Jun 08, 2020 · (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the U.S. Food and Drug Administration (FDA)

Estimated Reading Time: 6 mins

Preview / Show more

See Also: Family MedicalShow details

4 hours ago Oct 14, 2021 · The FDA’s Orphan Products Grants Program awards grants to clinical investigators to support the development of safe and effective medical products for patients …

Preview / Show more

See Also: Family MedicalShow details

1 hours ago Jul 08, 2022 · The FDA has authority to grant orphan drug designation to a drug or biological product to prevent, diagnose or treat a rare disease or condition. Orphan drug designation …

Preview / Show more

See Also: Family MedicalShow details

8 hours ago FDA Grants Orphan Drug Status to Mitapivat for … 8 hours ago Web The Food and Drug Administration (FDA) has granted Orphan Drug designation to mitapivat (AG-348; Agios …

Preview / Show more

See Also: TreatmentShow details

7 hours ago Jun 08, 2020 · The FDA’s Office of Orphan Drug Products grants orphan status to support the development of medicines for underserved patient populations, or rare disorders, that affect …

Preview / Show more

See Also: Family MedicalShow details

5 hours ago FDA Home. Developing Products for Rare Diseases & Conditions. This page searches the Orphan Drug Product designation database. Searches may be run by entering the product …

Preview / Show more

See Also: Family MedicalShow details

8 hours ago Jun 08, 2022 · Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Thalassemia June 8, 2020 CAMBRIDGE, Mass. , June 08, 2020 (GLOBE …

Preview / Show more

See Also: Family MedicalShow details

5 hours ago Jun 08, 2020 · Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the

Preview / Show more

See Also: Family MedicalShow details

8 hours ago --Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the U.S. Food and Drug Administration has granted …

Preview / Show more

See Also: Family MedicalShow details

4 hours ago Jun 08, 2020 · The FDA’s Office of Orphan Drug Products grants orphan status to support the development of medicines for underserved patient populations, or rare disorders, that affect …

Preview / Show more

See Also: Family MedicalShow details

9 hours ago 1 day ago · According to Fortune Business Insights™, the global Orphan Drugs Market size is expected to reach USD 340.84 Billion by 2027, at a CAGR of 10.5% during the forecast …

Preview / Show more

See Also: Family MedicalShow details

5 hours ago Jun 08, 2020 · CAMBRIDGE, Mass., June 08, 2020 -- Agios Pharmaceuticals, Inc. , a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced …

Preview / Show more

See Also: Family MedicalShow details

5 hours ago Agios Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company’s first-in-class pyruvate kinase-R (PKR) activator …

Preview / Show more

See Also: Family MedicalShow details

All Time (18 Recipes) Past 24 Hours Past Week Past monthFacebook Share Twitter Share LinkedIn Share Pinterest Share Reddit Share E-Mail Share

Please leave your comments here:

Related Topics

Healthy Care

Frequently Asked Questions

Is mitapivat FDA orphan drug designation coming?

June 2020 – Agios Pharmaceuticals, Inc. announced that the company had received the FDA Orphan Drug Designation for their pipeline candidate of Mitapivat for the treatment of Thalassemia.

What is the FDA’s Orphan Drug Designation program?

Supporting the development and evaluation of new treatments for rare diseases is a key priority for the FDA. The FDA has authority to grant orphan drug designation to a drug or biological product to prevent, diagnose or treat a rare disease or condition. Orphan drug designation qualifies sponsors for incentives including:

Is AstraZeneca’s enhertu an orphan drug?

May 2020 – AstraZeneca, and Daiichi Sankyo Company announced that the company had received the FDA Orphan Drug Designation for their product offering of Enhertu (trastuzumab deruxtecan) for the treatment of patients with gastric cancer, including gastroesophageal junction cancer.

What is the Orphan Products grants program?

The Orphan Products Grants Program is an incentive program that has been supporting clinical trial research since 1983 and has funded clinical trials that have facilitated the marketing approval of 70 products. Lack of natural history data presents a significant unmet need for rare disease product development.

Most Popular Search